More flight chaos for expats; European Union gives itself power to block vaccine shipments29th January 2021
Johnson & Johnson says its single-dose vaccine is 72 per cent effective in preventing COVID-19 in the United States but a lower rate of 66 per cent was observed globally in the large trial conducted across three continents and against multiple variants.
In the trial of nearly 44,000 volunteers, the level of protection against moderate and severe COVID-19 was 66 per cent in Latin America and just 57 per cent in South Africa, where a particularly worrying variant of the novel coronavirus is circulating.
Those results compare to the high bar set by two vaccines from Pfizer Inc/BioNTech SE and Moderna, which were around 95 per cent effective in preventing symptomatic illness in pivotal trials when given in two doses. Those trials, however, were conducted mainly in the United States and before the broad spread of new variants now under the spotlight.
Click here to read the story.